UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327

2019

Volltextzugriff (PDF)

ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5313-5327

2006

Volltextzugriff (PDF)

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1865-1878

2001

Volltextzugriff (PDF)

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Journal of clinical oncology, 2022-12, Vol.40 (34), p.3929-3939

2022

Volltextzugriff (PDF)

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply

The New England journal of medicine, 2019-10, Vol.381 (15), p.1492-1493

2019

Volltextzugriff (PDF)

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

Journal of clinical oncology, 2020-05, Vol.38 (13), p.1442-1454

2020

Volltextzugriff (PDF)

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Cancer, 2023-05, Vol.129 (9), p.1411-1418

2023

Volltextzugriff (PDF)

Oxaliplatin‐Related Acute Myelogenous Leukemia

The oncologist (Dayton, Ohio), 2006-03, Vol.11 (3), p.261-262

2006

Volltextzugriff (PDF)

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer : A us healthcare system perspective. the 5-year completed treatment analysis of the ATAC ('arimidex', tamoxifen alone or in combination) trial

Breast cancer research and treatment, 2007-12, Vol.106 (2), p.229-238

2007

Volltextzugriff (PDF)

Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

Cancer, 2004-08, Vol.101 (4), p.735-740

2004

Volltextzugriff (PDF)

Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer

Clinical breast cancer, 2005-10, Vol.6 (4), p.302-309

2005

Volltextzugriff (PDF)

The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer

Journal of the American College of Surgeons, 2001-07, Vol.193 (1), p.22-28

2001

Volltextzugriff (PDF)

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.420-420

2021

Volltextzugriff (PDF)

Genetic factors and colorectal cancer in Ashkenazi Jews

Familial cancer, 2004, Vol.3 (3-4), p.215-221

2004

Volltextzugriff (PDF)

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4626-4626

2020

Volltextzugriff (PDF)

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4621-4621

2020

Volltextzugriff (PDF)

Maintenance Olaparib for Metastatic Pancreatic Cancer

The New England journal of medicine, 2019-10, Vol.381 (15), p.1491-1493

2019

Volltextzugriff (PDF)

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g BRCA m) who have not progressed following first-line chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS4149-TPS4149

2015

Volltextzugriff (PDF)

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

Cancer investigation, 2007-01, Vol.25 (5), p.366-371

2007

Volltextzugriff (PDF)

Cancer in Jews: introduction and overview

Familial cancer, 2004, Vol.3 (3-4), p.177-192

2004

Volltextzugriff (PDF)

MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

Annals of oncology, 2021-07, Vol.32, p.S319-S319

2021

Volltextzugriff (PDF)

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.412-412

2021

Volltextzugriff (PDF)

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.378-378

2021

Volltextzugriff (PDF)

Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4115-4115

2018

Volltextzugriff (PDF)

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16800-e16800

2020

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Oxaliplatin‐Related Acute Myelogenous Leukemia

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer : A us healthcare system perspective. the 5-year completed treatment analysis of the ATAC ('arimidex', tamoxifen alone or in combination) trial

Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer

The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Genetic factors and colorectal cancer in Ashkenazi Jews

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Maintenance Olaparib for Metastatic Pancreatic Cancer

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g BRCA m) who have not progressed following first-line chemotherapy

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

Cancer in Jews: introduction and overview

MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer

Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC)

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)

Suchergebnisse filtern